Cargando…
Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen
BACKGROUND: Previous studies confirmed that most neoantigens predicted by algorithms do not work in clinical practice, and experimental validations remain indispensable for confirming immunogenic neoantigens. In this study, we identified the potential neoantigens with tetramer staining, and establis...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124323/ https://www.ncbi.nlm.nih.gov/pubmed/37076248 http://dx.doi.org/10.1136/jitc-2022-006334 |
_version_ | 1785029816397856768 |
---|---|
author | Chen, Pu Chen, Dongbo Bu, Dechao Gao, Jie Qin, Wanying Deng, Kangjian Ren, Liying She, Shaoping Xu, Wentao Yang, Yao Xie, Xingwang Liao, Weijia Chen, Hongsong |
author_facet | Chen, Pu Chen, Dongbo Bu, Dechao Gao, Jie Qin, Wanying Deng, Kangjian Ren, Liying She, Shaoping Xu, Wentao Yang, Yao Xie, Xingwang Liao, Weijia Chen, Hongsong |
author_sort | Chen, Pu |
collection | PubMed |
description | BACKGROUND: Previous studies confirmed that most neoantigens predicted by algorithms do not work in clinical practice, and experimental validations remain indispensable for confirming immunogenic neoantigens. In this study, we identified the potential neoantigens with tetramer staining, and established the Co-HA system, a single-plasmid system coexpressing patient human leukocyte antigen (HLA) and antigen, to detect the immunogenicity of neoantigens and verify new dominant hepatocellular carcinoma (HCC) neoantigens. METHODS: First, we enrolled 14 patients with HCC for next-generation sequencing for variation calling and predicting potential neoantigens. Then, the Co-HA system was established. To test the feasibility of the system, we constructed target cells coexpressing HLA-A*11:01 and the reported KRAS G12D neoantigen as well as specific T-cell receptor (TCR)-T cells. The specific cytotoxicity generated by this neoantigen was shown using the Co-HA system. Moreover, potential HCC-dominant neoantigens were screened out by tetramer staining and validated by the Co-HA system using methods including flow cytometry, enzyme-linked immunospot assay and ELISA. Finally, antitumor test in mouse mode and TCR sequencing were performed to further evaluate the dominant neoantigen. RESULTS: First, 2875 somatic mutations in 14 patients with HCC were identified. The main base substitutions were C>T/G>A transitions, and the main mutational signatures were 4, 1 and 16. The high-frequency mutated genes included HMCN1, TTN and TP53. Then, 541 potential neoantigens were predicted. Importantly, 19 of the 23 potential neoantigens in tumor tissues also existed in portal vein tumor thrombi. Moreover, 37 predicted neoantigens restricted by HLA-A*11:01, HLA-A*24:02 or HLA-A*02:01 were performed by tetramer staining to screen out potential HCC-dominant neoantigens. HLA-A*24:02-restricted epitope 5'-FYAFSCYYDL-3' and HLA-A*02:01-restricted epitope 5'-WVWCMSPTI-3' demonstrated strong immunogenicity in HCC, as verified by the Co-HA system. Finally, the antitumor efficacy of 5'-FYAFSCYYDL-3'-specific T cells was verified in the B-NDG-B2m(tm1)Fcrn(tm1(mB2m)) mouse and their specific TCRs were successfully identified. CONCLUSION: We found the dominant neoantigens with high immunogenicity in HCC, which were verified with the Co-HA system. |
format | Online Article Text |
id | pubmed-10124323 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-101243232023-04-25 Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen Chen, Pu Chen, Dongbo Bu, Dechao Gao, Jie Qin, Wanying Deng, Kangjian Ren, Liying She, Shaoping Xu, Wentao Yang, Yao Xie, Xingwang Liao, Weijia Chen, Hongsong J Immunother Cancer Immunotherapy Biomarkers BACKGROUND: Previous studies confirmed that most neoantigens predicted by algorithms do not work in clinical practice, and experimental validations remain indispensable for confirming immunogenic neoantigens. In this study, we identified the potential neoantigens with tetramer staining, and established the Co-HA system, a single-plasmid system coexpressing patient human leukocyte antigen (HLA) and antigen, to detect the immunogenicity of neoantigens and verify new dominant hepatocellular carcinoma (HCC) neoantigens. METHODS: First, we enrolled 14 patients with HCC for next-generation sequencing for variation calling and predicting potential neoantigens. Then, the Co-HA system was established. To test the feasibility of the system, we constructed target cells coexpressing HLA-A*11:01 and the reported KRAS G12D neoantigen as well as specific T-cell receptor (TCR)-T cells. The specific cytotoxicity generated by this neoantigen was shown using the Co-HA system. Moreover, potential HCC-dominant neoantigens were screened out by tetramer staining and validated by the Co-HA system using methods including flow cytometry, enzyme-linked immunospot assay and ELISA. Finally, antitumor test in mouse mode and TCR sequencing were performed to further evaluate the dominant neoantigen. RESULTS: First, 2875 somatic mutations in 14 patients with HCC were identified. The main base substitutions were C>T/G>A transitions, and the main mutational signatures were 4, 1 and 16. The high-frequency mutated genes included HMCN1, TTN and TP53. Then, 541 potential neoantigens were predicted. Importantly, 19 of the 23 potential neoantigens in tumor tissues also existed in portal vein tumor thrombi. Moreover, 37 predicted neoantigens restricted by HLA-A*11:01, HLA-A*24:02 or HLA-A*02:01 were performed by tetramer staining to screen out potential HCC-dominant neoantigens. HLA-A*24:02-restricted epitope 5'-FYAFSCYYDL-3' and HLA-A*02:01-restricted epitope 5'-WVWCMSPTI-3' demonstrated strong immunogenicity in HCC, as verified by the Co-HA system. Finally, the antitumor efficacy of 5'-FYAFSCYYDL-3'-specific T cells was verified in the B-NDG-B2m(tm1)Fcrn(tm1(mB2m)) mouse and their specific TCRs were successfully identified. CONCLUSION: We found the dominant neoantigens with high immunogenicity in HCC, which were verified with the Co-HA system. BMJ Publishing Group 2023-04-17 /pmc/articles/PMC10124323/ /pubmed/37076248 http://dx.doi.org/10.1136/jitc-2022-006334 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Immunotherapy Biomarkers Chen, Pu Chen, Dongbo Bu, Dechao Gao, Jie Qin, Wanying Deng, Kangjian Ren, Liying She, Shaoping Xu, Wentao Yang, Yao Xie, Xingwang Liao, Weijia Chen, Hongsong Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen |
title | Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen |
title_full | Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen |
title_fullStr | Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen |
title_full_unstemmed | Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen |
title_short | Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen |
title_sort | dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient hla and antigen |
topic | Immunotherapy Biomarkers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124323/ https://www.ncbi.nlm.nih.gov/pubmed/37076248 http://dx.doi.org/10.1136/jitc-2022-006334 |
work_keys_str_mv | AT chenpu dominantneoantigenverificationinhepatocellularcarcinomabyasingleplasmidsystemcoexpressingpatienthlaandantigen AT chendongbo dominantneoantigenverificationinhepatocellularcarcinomabyasingleplasmidsystemcoexpressingpatienthlaandantigen AT budechao dominantneoantigenverificationinhepatocellularcarcinomabyasingleplasmidsystemcoexpressingpatienthlaandantigen AT gaojie dominantneoantigenverificationinhepatocellularcarcinomabyasingleplasmidsystemcoexpressingpatienthlaandantigen AT qinwanying dominantneoantigenverificationinhepatocellularcarcinomabyasingleplasmidsystemcoexpressingpatienthlaandantigen AT dengkangjian dominantneoantigenverificationinhepatocellularcarcinomabyasingleplasmidsystemcoexpressingpatienthlaandantigen AT renliying dominantneoantigenverificationinhepatocellularcarcinomabyasingleplasmidsystemcoexpressingpatienthlaandantigen AT sheshaoping dominantneoantigenverificationinhepatocellularcarcinomabyasingleplasmidsystemcoexpressingpatienthlaandantigen AT xuwentao dominantneoantigenverificationinhepatocellularcarcinomabyasingleplasmidsystemcoexpressingpatienthlaandantigen AT yangyao dominantneoantigenverificationinhepatocellularcarcinomabyasingleplasmidsystemcoexpressingpatienthlaandantigen AT xiexingwang dominantneoantigenverificationinhepatocellularcarcinomabyasingleplasmidsystemcoexpressingpatienthlaandantigen AT liaoweijia dominantneoantigenverificationinhepatocellularcarcinomabyasingleplasmidsystemcoexpressingpatienthlaandantigen AT chenhongsong dominantneoantigenverificationinhepatocellularcarcinomabyasingleplasmidsystemcoexpressingpatienthlaandantigen |